Intech Investment Management LLC Acquires Shares of 16,437 OmniAb, Inc. (NASDAQ:OABI)

Intech Investment Management LLC acquired a new stake in shares of OmniAb, Inc. (NASDAQ:OABI) in the third quarter, Holdings Channel reports. The firm acquired 16,437 shares of the company’s stock, valued at approximately $70,000.

Several other large investors also recently added to or reduced their stakes in the stock. Atria Investments Inc bought a new stake in shares of OmniAb during the third quarter valued at approximately $148,000. Isthmus Partners LLC increased its holdings in OmniAb by 37.2% during the 2nd quarter. Isthmus Partners LLC now owns 528,385 shares of the company’s stock worth $1,981,000 after purchasing an additional 143,387 shares during the period. Rice Hall James & Associates LLC increased its holdings in OmniAb by 6.4% during the 3rd quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock worth $11,515,000 after purchasing an additional 163,038 shares during the period. The Manufacturers Life Insurance Company bought a new stake in OmniAb during the 2nd quarter valued at $147,000. Finally, Sei Investments Co. lifted its holdings in shares of OmniAb by 11.0% in the 2nd quarter. Sei Investments Co. now owns 29,024 shares of the company’s stock worth $109,000 after buying an additional 2,888 shares during the period. 72.08% of the stock is owned by hedge funds and other institutional investors.

OmniAb Price Performance

Shares of OABI stock opened at $4.02 on Monday. The company has a market cap of $567.70 million, a P/E ratio of -6.48 and a beta of -0.14. The stock’s 50-day moving average is $4.04 and its 200 day moving average is $4.20. OmniAb, Inc. has a 1-year low of $3.56 and a 1-year high of $6.72.

Wall Street Analyst Weigh In

OABI has been the topic of several research reports. Benchmark restated a “buy” rating and set a $8.00 price target on shares of OmniAb in a research note on Thursday, November 14th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $7.00 price target on shares of OmniAb in a research report on Friday, August 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of OmniAb in a research note on Thursday, November 14th.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.